创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

循环游离线粒体DNA作为新型肿瘤液体活检标志物的研究进展

Research Progress of Circulating Cell Free Mitochondrial DNA as Novel Tumor Markers for Liquid Biopsy

  • 摘要: 恶性肿瘤是导致人类死亡的主要原因之一,早期诊断和精准治疗能够显著改善肿瘤患者预后。随着液体活检技术的迅速发展,循环肿瘤细胞、外泌体、循环肿瘤DNA等新型肿瘤标志物被发现并展现出巨大的临床应用潜力,为肿瘤的诊治提供了更为精准的检测手段,逐渐成为研究热点。和循环游离核DNA相比,循环游离线粒体DNA(cf-mtDNA)具有基因组小、拷贝数多、突变频率高的特点,在肿瘤诊断和治疗检测中具有独特的优势,显示出良好的应用前景。综述系统介绍了循环cf-mtDNA的特点、检测技术、分析指标,以及cf-mtDNA在肿瘤早期诊断、治疗监测、预后评估中的应用价值。

     

    Abstract: Malignant tumor is one of the main causes of human death. Early diagnosis and precise treatment can significantly improve the prognosis of cancer patients. With the rapid development of liquid biopsy technology, new tumor markers such as circulating tumor cells, exosomes, circulating tumor DNA and circulating free DNA have been found to have become a research detection with tremendous potential for clinical application, providing more precise detection methods for tumor diagnosis and treatment. Compared with cell free nuclear DNA, cell free mitochondrial DNA (cf-mtDNA) has such characteristics as small genome, multiple copy numbers and high mutation frequency. The unique advantages of cf-mtDNA in tumor diagnosis and treatment have made it more attractive with a promising application prospect. This article reviews the characteristics, detection techniques, and analytical indicators of circulating cf-mtDNA, as well as the application value of cf-mtDNA in early diagnosis, precision medicine, efficacy monitoring, and prognosis prediction.

     

/

返回文章
返回